BR0214437A - Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um composto - Google Patents
Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um compostoInfo
- Publication number
- BR0214437A BR0214437A BR0214437-9A BR0214437A BR0214437A BR 0214437 A BR0214437 A BR 0214437A BR 0214437 A BR0214437 A BR 0214437A BR 0214437 A BR0214437 A BR 0214437A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- compound
- group
- modulating
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33445301P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/036128 WO2003048130A2 (en) | 2001-11-30 | 2002-11-26 | Peroxisome proliferator activated receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0214437A true BR0214437A (pt) | 2004-10-13 |
Family
ID=23307275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0214437-9A BR0214437A (pt) | 2001-11-30 | 2002-11-26 | Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um composto |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7544812B2 (enExample) |
| EP (1) | EP1453811A2 (enExample) |
| JP (1) | JP2005517643A (enExample) |
| KR (1) | KR20050044606A (enExample) |
| CN (1) | CN1582279A (enExample) |
| AU (1) | AU2002356927A1 (enExample) |
| BR (1) | BR0214437A (enExample) |
| CA (1) | CA2468846A1 (enExample) |
| CO (1) | CO5640129A2 (enExample) |
| EA (1) | EA007163B1 (enExample) |
| HR (1) | HRP20040469A2 (enExample) |
| HU (1) | HUP0402486A3 (enExample) |
| IL (1) | IL161578A0 (enExample) |
| MX (1) | MXPA04005123A (enExample) |
| NO (1) | NO20042737L (enExample) |
| NZ (1) | NZ532909A (enExample) |
| PL (1) | PL370515A1 (enExample) |
| WO (1) | WO2003048130A2 (enExample) |
| ZA (1) | ZA200404173B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0311834A (pt) | 2002-06-19 | 2005-04-12 | Lilly Co Eli | Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável |
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| DE10351859A1 (de) * | 2003-11-06 | 2005-06-09 | Beiersdorf Ag | Emulsionen mit zwei Verdickungsmitteln |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| NZ553566A (en) * | 2004-09-28 | 2010-11-26 | Allergan Inc | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same |
| BRPI0713320A2 (pt) | 2006-06-20 | 2012-02-07 | Wyeth Corp | inibidores de canal de potássio imidazola kvl.5 |
| FR2903984B1 (fr) * | 2006-07-24 | 2008-10-03 | Genfit Sa | Derives d'imidazolones substitues, preparation et utilisations |
| WO2008094860A2 (en) | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
| EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| CN101875636B (zh) * | 2010-05-18 | 2012-01-04 | 浙江大学 | 咪唑啉-2,4-二酮类衍生物及制备方法和用途 |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法 |
| CN115894379B (zh) * | 2022-01-20 | 2025-06-27 | 哈尔滨三联药业股份有限公司 | 海因类化合物及其医药用途 |
| CN114835655A (zh) * | 2022-04-14 | 2022-08-02 | 河南师范大学 | 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3452041A (en) * | 1965-05-19 | 1969-06-24 | American Home Prod | Hydantoin compounds and methods of preparation |
| CA1176261A (en) | 1976-06-03 | 1984-10-16 | Albert G. Caldwell | Hydantoin derivatives |
| GB1601310A (en) | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
| JPS59159163A (ja) * | 1983-03-01 | 1984-09-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−感光材料 |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| WO1998039303A1 (en) * | 1997-03-03 | 1998-09-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| AU7073400A (en) | 1999-08-27 | 2001-03-26 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
-
2002
- 2002-11-26 CN CNA028238001A patent/CN1582279A/zh active Pending
- 2002-11-26 EA EA200400748A patent/EA007163B1/ru not_active IP Right Cessation
- 2002-11-26 HR HR20040469A patent/HRP20040469A2/hr not_active Application Discontinuation
- 2002-11-26 WO PCT/US2002/036128 patent/WO2003048130A2/en not_active Ceased
- 2002-11-26 NZ NZ532909A patent/NZ532909A/en unknown
- 2002-11-26 BR BR0214437-9A patent/BR0214437A/pt not_active IP Right Cessation
- 2002-11-26 AU AU2002356927A patent/AU2002356927A1/en not_active Abandoned
- 2002-11-26 US US10/496,770 patent/US7544812B2/en not_active Expired - Fee Related
- 2002-11-26 CA CA002468846A patent/CA2468846A1/en not_active Abandoned
- 2002-11-26 EP EP02804416A patent/EP1453811A2/en not_active Withdrawn
- 2002-11-26 IL IL16157802A patent/IL161578A0/xx unknown
- 2002-11-26 JP JP2003549322A patent/JP2005517643A/ja active Pending
- 2002-11-26 MX MXPA04005123A patent/MXPA04005123A/es unknown
- 2002-11-26 KR KR1020047008021A patent/KR20050044606A/ko not_active Withdrawn
- 2002-11-26 HU HU0402486A patent/HUP0402486A3/hu unknown
- 2002-11-26 PL PL02370515A patent/PL370515A1/xx not_active Application Discontinuation
-
2004
- 2004-05-27 CO CO04049275A patent/CO5640129A2/es not_active Application Discontinuation
- 2004-05-27 ZA ZA200404173A patent/ZA200404173B/en unknown
- 2004-06-29 NO NO20042737A patent/NO20042737L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20042737L (no) | 2004-08-17 |
| PL370515A1 (en) | 2005-05-30 |
| US7544812B2 (en) | 2009-06-09 |
| WO2003048130A2 (en) | 2003-06-12 |
| HUP0402486A3 (en) | 2007-05-02 |
| CO5640129A2 (es) | 2006-05-31 |
| HRP20040469A2 (en) | 2004-10-31 |
| CN1582279A (zh) | 2005-02-16 |
| AU2002356927A1 (en) | 2003-06-17 |
| KR20050044606A (ko) | 2005-05-12 |
| CA2468846A1 (en) | 2003-06-12 |
| EA200400748A1 (ru) | 2004-12-30 |
| JP2005517643A (ja) | 2005-06-16 |
| EA007163B1 (ru) | 2006-08-25 |
| WO2003048130A3 (en) | 2003-11-20 |
| US20050020652A1 (en) | 2005-01-27 |
| MXPA04005123A (es) | 2005-02-17 |
| HUP0402486A2 (hu) | 2005-03-29 |
| EP1453811A2 (en) | 2004-09-08 |
| IL161578A0 (en) | 2004-09-27 |
| ZA200404173B (en) | 2005-08-23 |
| NZ532909A (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0214437A (pt) | Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um composto | |
| BR0009864A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto | |
| BR9911420A (pt) | Derivados de epotilona e sìntese e uso dos mesmos | |
| CN101945853A (zh) | 选择性雄激素受体调节剂(sarm)及其应用 | |
| BRPI0417687A (pt) | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade | |
| PE20010613A1 (es) | Antagonistas de la hormona concentradora de la melanina | |
| AR045173A1 (es) | Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio | |
| DK1349843T3 (da) | Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer | |
| BR9812095A (pt) | Compostos de indol como inibidores de cox-2 | |
| MY154836A (en) | Activating agent for peroxisome prolifrator activated receptor ? | |
| CY1110969T1 (el) | 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ | |
| BRPI0510623A (pt) | compostos de derivados de prolina e morfolina | |
| CO6140035A2 (es) | Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1) | |
| EA200300716A1 (ru) | Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6 | |
| AR046452A1 (es) | Derivados de quinazolina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento con efecto antiproliferativo | |
| IT1250049B (it) | Composti triciclici. | |
| MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| TW200700069A (en) | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | |
| EA200200232A1 (ru) | Интерлейкин-5 ингибирующие производные 6-азаурацила | |
| EP1948161A4 (en) | METHOD FOR PREVENTING AND TREATING PPAR-MEDIATED CONDITIONS WITH MACELIGNAN | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| ATE455761T1 (de) | Neue atorvastatinsalze und pharmazeutische zusammensetzungen, die diese enthalten | |
| MA30540B1 (fr) | Derives de quinolines et compositions pharmaceutiques de ces derives. | |
| ATE484502T1 (de) | Neue verbindungen | |
| BR0317693A (pt) | Derivados de epotilona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009. |